Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

AstraZeneca's Imfinzi (durvalumab) wins EU approval for resectable gastric and gastroesophageal junction cancers following Ph3 success
Antibody, cancer, monoclonal antibody, gastric cancer, PD-L1 inhibitor, combination therapy - Read more

Roche, Nvidia expand AI partnership with 2,176 Blackwell GPUs for drug and diagnostic development
Technology partnership, AI/ML, drug discovery, diagnostics, manufacturing, digital health - Read more

Samsung Bioepis, Epis NexLab, G2GBIO collaborate on long-acting semaglutide using microsphere technology, financial terms confidential
Research collaboration, licensing deal, drug delivery, sustained-release formulation, diabetes - Read more

Zevra Therapeutics sells SDX portfolio including AZSTARYS to Commave Therapeutics for $50 million
Asset sale, rare disease, neurological, small molecule - Read more

The pathway to FDA can be difficult to navigate when precedent is limited, and frameworks are thin.

Facet specializes in helping emerging biotech teams understand what your program must demonstrate, how regulators are likely to evaluate the evidence, and what constitutes a viable, and ultimately, approvable, path forward.

It’s a regulatory strategy that starts where it should: with your science and your goals. Not the other way around.

Book a free 30-minute intro session with Facet → click here

Eli Lilly's Ebglyss IL-13 inhibitor hits Ph3 endpoints in pediatric atopic dermatitis, setting up label expansion
Antibody, autoimmune, monoclonal antibody, atopic dermatitis, IL-13 inhibitor, pediatric - Read more

Bayer's Kerendia (finerenone) hits Ph3 primary endpoint in non-diabetic chronic kidney disease patients
Small molecule, kidney disease, mineralocorticoid receptor antagonist, chronic kidney disease, finerenone - Read more

CytomX Therapeutics reports positive Ph1 data for Varseta-M antibody-drug conjugate in colorectal cancer
Antibody-drug conjugate, cancer, ADC, colorectal cancer, masked antibody, monotherapy - Read more

Structure Therapeutics' aleniglipron shows up to 15% weight loss in Ph2 obesity trial
Small molecule, metabolic, GLP-1 agonist, obesity, oral formulation - Read more

Almirall's lebrikizumab shows positive Ph3 results in pediatric patients with moderate-to-severe atopic dermatitis
Antibody, autoimmune, monoclonal antibody, atopic dermatitis, pediatric population, IL-13 inhibitor - Read more

Unnatural Products raises $45M Series B, macrocyclic peptides for undruggable targets
Macrocyclic peptides, metabolic disease, platform technology, preclinical - Read more

Connext raises $15B Series C, recombinant protein treatment for Dupuytren's contracture
Recombinant protein, rare disease, clinical-stage, biopharmaceuticals - Read more

CytomX Therapeutics raises $250M public offering, developing masked conditionally activated biologics
Masked biologics, oncology, antibody, clinical-stage - Read more

Federal judge blocks RFK Jr.'s childhood vaccine schedule changes, halts CDC advisory panel appointments
Vaccine, infectious disease, regulatory, operational - Read more

Amgen, GSK medications now available through White House's TrumpRx direct-to-consumer platform with significant discounts
Biosimilar, autoimmune, strategic, cost reduction, operational - Read more

CirCode Biomed receives FDA clearance for US clinical trial of circular RNA therapy
Circular RNA, regulatory, strategic, competitive - Read more [Paywall]

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Astellas, CytomX Therapeutics end $1.6B T-cell engager partnership after six years
Partnership termination, oncology, T-cell engager, bispecific antibody, milestone payments - Read more

BioMarin pauses Voxzogo dosing and enrollment in Turner syndrome studies following safety signal reports
Protein therapy, genetic disorders, CNP analog, achondroplasia, Turner syndrome, safety signal - Read more

Nerviano Medical Sciences discontinues Ph2 trial of NMS-153 targeting MPS1 for hepatocellular carcinoma due to lack of efficacy
Small molecule, cancer, MPS1 inhibitor, hepatocellular carcinoma, combination therapy, checkpoint inhibitor - Read more

J&J files trade secret lawsuit against former employee now at Summit Therapeutics for alleged document theft
Bispecific antibody, oncology, competitive, strategic, operational - Read more

White House pressures Health Secretary RFK Jr. to soften vaccine skepticism amid electoral concerns and policy reversals
Vaccines, infectious disease, regulatory, operational - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here